Feb 13–16, 2028 | Fairmont Monte Carlo, Monte Carlo, Monaco
Scientific Organizers:
Christopher D. Buckley, Ellen M. Gravallese, and Luke Devey
-
Scientific Organizers: Christopher D. Buckley, Ellen M. Gravallese, and Luke Devey
Christopher D. Buckley, PhD
Kennedy Institute of Rheumatology
Ellen M. Gravallese, MD
Brigham and Women's Hospital
Luke Devey, MD, PhD
Quell Therapeutics
Important Deadlines
Meeting Summary
Autoimmune and autoinflammatory diseases are major causes of lifelong morbidity and healthcare burden, affecting multiple organ systems through overlapping but incompletely understood genetic, immune, stromal, and environmental mechanisms. Rapid advances in human genetics, single-cell and spatial profiling, disease modeling, immune monitoring, and therapeutic engineering now make it possible to connect causal pathways to tissue pathology and therapeutic response with unprecedented resolution. Yet clinical care remains dominated by broad diagnostic categories and chronic immunomodulation, and many patients cycle empirically through therapies without durable disease control.
This Keystone Symposia conference on Autoimmunity and Autoinflammation: From Genes and Cells to Tissues and Therapies will define the mechanistic and translational steps required to move from pathway discovery to disease interception, patient stratification, durable immune reset, and tissue restoration. It will examine how (1) genetic risk becomes a disease-relevant cell state, (2) blood and tissue biomarkers can guide therapeutic choice, and (3) emerging modalities—including targeted biologics, immune agonists, T-cell engagers, engineered regulatory cells, autologous and allogeneic CAR-T, and in vivo cell engineering—can be deployed rationally across autoimmune and autoinflammatory diseases. Emphasis will be placed on lupus, systemic sclerosis, inflammatory arthritis, inflammatory bowel disease, immune-mediated kidney disease, and genetically defined autoinflammatory syndromes. Attendees should leave with a clearer framework for selecting mechanisms, patients, endpoints, and translational strategies most likely to produce durable benefit.
The conference deliberately integrates human genetics, innate and adaptive immunology, mucosal and stromal biology, single-cell and spatial technologies, clinical trial science, cell and gene engineering, and drug development. Academic mechanistic investigators are paired with clinician-scientists and biotechnology/pharmaceutical leaders so that each stage of the translational chain—mechanism, human validation, therapeutic design, clinical development, and implementation—is represented. The cross-disease format is intended to expose shared principles of immune dysregulation while also identifying the tissue- and disease-specific constraints that determine therapeutic success.
The field is entering a period in which immune-mediated disease may no longer be treated solely by indefinite suppression of inflammatory pathways. Deep B-cell depletion, T-cell engagers, engineered regulatory cells, allogeneic platforms, and in vivo cell engineering are creating realistic routes toward time-limited therapies and immune system reset, while tissue profiling is revealing why apparently similar patients respond differently. By bringing foundational immunology together with rapidly maturing therapeutic platforms, this conference will provide a timely forum to define what a curative or durable remission strategy should look like, what biological and clinical evidence will be required, and how these approaches can be made safe, scalable, and broadly accessible.
Unique Career Development Opportunities
This meeting will feature a Career Roundtable where trainees and early-career investigators will have the opportunity to interact with field leaders from across academic and industry sectors for essential career development advice and networking opportunities. Find out more about Career Roundtables here: https://www.keystonesymposia.org/diversity/career-development-initiatives
SPECIAL RECOGNITION:
KEYSTONE SYMPOSIA THANKS OUR SPONSOR(S) FOR GENEROUSLY SUPPORTING THIS MEETING:
KEYSTONE SYMPOSIA THANKS OUR MEETING EXHIBITOR(S):
KEYSTONE SYMPOSIA THANKS THESE DONOR(S) FOR GENEROUSLY SUPPORTING THIS MEETING:
THESE COMPANIES HAVE GENEROUSLY AGREED TO COVER THE EXPENSES OF THEIR EMPLOYEES WHO ARE SPEAKING AT THIS MEETING:
GRANT RECOGNITION:
KEYSTONE SYMPOSIA THANKS OUR GIFT-IN-KIND MEDIA SPONSORS
Subscribe for Updates